Company & Sponsor Intelligence
Fenix Innovation Group
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting1
Completed1
Countries1
Therapeutic footprint
autismneurodevelopmental_other
Indexed studies
NCT07257978Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
neurodevelopmental_other · AustraliaPHASE2, PHASE3
neurodevelopmental_other · AustraliaPHASE2, PHASE3
NCT05516407Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
autism · AustraliaPHASE1, PHASE2
autism · AustraliaPHASE1, PHASE2
NCT05626959Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder
autism · AustraliaPHASE2,PHASE3
autism · AustraliaPHASE2,PHASE3
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →